Disc Medicine, Inc. (IRON) research: valuation against peers, fundamentals over time, risk and news coverage
ChartVs peersValuationValue mapQuartersScaleMarginsTrajectoryCash qualityPer shareReinvestmentBalance sheetStreetRiskSeasonalityOur coverage
IRON
Disc Medicine, Inc.USD
76.51
-0.43% today
Market cap
—
P/E trailing
—
P/E forward
—
EV/EBITDA
—
Op margin
—
Rev growth
—
Div yield
—
Beta
—
Price navigator — IRON
No data in this window.
INDY NEWS coverage of IRON1
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBULLISHDisc Medicine Wins Analyst Backing on Blood Disorder Trial Data
Two brokerages reiterated favorable ratings on Disc Medicine following trial data for its polycythemia treatment, a disorder marked by excess red blood cells.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.